|
- Sirolimus Uses, Side Effects Warnings - Drugs. com
Sirolimus weakens your body's immune system, to help keep it from "rejecting" a transplanted organ such as a kidney Organ rejection happens when the immune system treats the new organ as an invader and attacks it Sirolimus is used with other medicines to prevent organ rejection after a kidney transplant
- Sirolimus - Wikipedia
Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumour (PEComa)
- Sirolimus (oral route) - Mayo Clinic
Sirolimus is a very strong medicine It can cause side effects that can be very serious, such as kidney problems It may also reduce the body's ability to fight infections You and your doctor should talk about the benefits of this medicine as well as the risks
- Sirolimus (Rapamune): Uses Side Effects - Cleveland Clinic
Sirolimus is a medication that decreases your immune system’s response to a transplanted organ to prevent rejection It can also treat lymphangioleiomyomatosis This condition causes damage to your lung tissue that results in an inability of fully oxygenate blood, fluid in your lungs or a collapsed lung
- Sirolimus (Rapamune) - Uses, Side Effects, and More
Overview: Sirolimus is used to prevent kidney transplant rejection and to treat lymphangioleiomyomatosis (LAM), a rare lung disease It prevents organ rejection by suppressing the
- Sirolimus: Side Effects, Uses, Dosage, Interactions, Warnings
Sirolimus is a prescription medication used for the prevention of renal transplant rejection and to treat a rare lung disorder called lymphangioleiomyomatosis (LAM) Learn about dosages, side effects, drug interactions, and warnings
- SIROLIMUS tablet - DailyMed
Sirolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged ≥13 years receiving renal transplants: Patients at low-to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids CsA withdrawal is recommended 2 to 4 months after transplantation
- Sirolimus: Dosage, Mechanism Onset of Action, Half-Life . . .
Sirolimus inhibits T-lymphocyte activation and proliferation in response to antigenic and cytokine stimulation and inhibits antibody production Its mechanism differs from other immunosuppressants
|
|
|